Swiss Biotech Industry
With over 19,000 jobs and CHF 9.25 billion (+11%) turnover in 2010, the biotech industry has now cemented its status as an innovative force in the Swiss economy. That is why Ernst & Young, SWX Swiss Exchange, the State Secretariat for Economic Affairs (SECO), the Innovation Promotion Agency (KTI/CTI), the Swiss National Science Foundation, the Federal Institute of Intellectual Property, the Swiss Biotech Association, the Swiss Technology Transfer Association (swiTT), the Swiss Private Equity and Corporate Finance Association (SECA) and the national competency network for biotechnology (biotechnet Switzerland) are already publishing the fourth edition of the Swiss Biotech Report.
The latest Swiss Biotech Report 2011 reveals that despite a difficult economic environment in 2010, the turnover of the sector stabilized at CHF 9.2 billion compared with CHF 9.3 billion in 2009, and more than CHF 255 million in new financing was raised by Swiss biotech companies. The result must be considered as very good, taking into account the significant foreign exchange impact caused by the weakening US dollar and the euro. Without that, the industry’s revenue picture would actually have increased by approximately 11%. Research and development investment in Swiss biotech continues at high levels comparable to the 2009 figures. The latest Swiss Biotech Report 2011 reveals that despite a difficult economic environment in 2010, the turnover of the sector stabilized at CHF 9.2 billion compared with CHF 9.3 billion in 2009, and more than CHF 255 million in new financing was raised by Swiss biotech companies. The result must be considered as very good, taking into account the significant foreign exchange impact caused by the weakening US dollar and the euro. Without that, the industry’s revenue picture would actually have increased by approximately 11%. Research and development investment in Swiss biotech continues at high levels comparable to the 2009 figures.
Swiss Biotech Report 2011: Sustainability wins over the years
The latest data in the Swiss Biotech Report 2011 reveals that the Swiss biotech industry continued to grow in 2010. The number of people employed in the sector grew to 19,500, up slightly from 2009. Annual turnover stayed remarkably stable at CHF 9.2 billion, compared to 9.3 billion the previous year. Privately-owned biotech financial results and headcounts remained stable, which shows that the private equity system is working still fine. The financing environment in 2010 was again challenging. Overall, the Swiss biotechnology industry was only able to raise CHF 255 million of new money – a setback compared with 2009. However, this decrease needs to be seen in the context of the extensive financing that took place in the previoius year. In part the harsh financing environment can also be explained by the somewhat delayed impact of the global financial crisis and the limited exit opportunities via trade sales or IPOs.
The report also reveals that in 2010 the US company EffRx Pharmaceuticals relocated from Florida to Lausanne and InterMune Inc. California, opened a subsidiary in Switzerland to coordinate its European activities.
"Overall the Swiss biotechnology industry shows strong, sustainable quality and this is due to the business friendly conditions provided by Switzerland. The competitive environment in Switzerland is well-supported through the close ties between leading universities and research-oriented industrial players. It is a further strength of the location Switzerland,” comments Domenico P. Alexakis, CEO of the Swiss Biotech Association, on the Swiss Biotech Report 2011. Switzerland has a world-wide reputation for research thanks to a unique combination of dedicated researchers, industrial players, and the contribution of the Swiss National Fund. One leading indicator of the research strength is the number of new patents registered.
Switzerland at BIO 2011, Washington
17 companies and stakeholder organizations will be represented in the Swiss Pavilion (booth no. 5023). The Pavilion is organized by Osec in close co-operation with Swiss Biotech and the Swiss Business Hub USA. Osec is the umbrella organization for the promotion of exports, imports and investment of Switzerland as a business location. Swiss Know-How at BIO 2011 comprises amongst others two panel discussions on June 28, 09:30 – 10:15. The topic is on Innovative Platforms for Biology Protein Therapeutics. Switzerland participates also at various gatherings at the Swiss Pavilion and partners up with other Biotech hot spots.
further information
7.8 MB / 10.05.2021 09:29
3.4 MB / 10.05.2021 09:29
3.3 MB / 14.08.2018 16:31
4.1 MB / 07.06.2017 15:53
2.8 MB / 07.06.2017 15:51
2.7 MB / 14.08.2014 13:37
3.1 MB / 14.08.2014 13:36
3.7 MB / 14.08.2014 13:35
2.1 MB / 30.09.2011 15:21
2.3 MB / 30.09.2011 15:21